Corrections to “Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Ann Oncol 2018; 29: iv41–iv50 (doi:10.1093/annonc/mdy146) The following corrections have been made: In “Table 2. Prognostification of WM (IPSSWM) (adapted from [12])” The reference number 12 Has been replaced with: 19 In “Table 3. Indications for initiation of therapy in patients with WM [31]” IgM levels ≥ 6000 mg/L Has been replaced with: IgM levels > 60 g/L Under the section “Management: Asymptomatic patients” IgM levels ≥ 6000 mg/L Has been replaced with: IgM levels > 60 g/L Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 29PreviewWaldenström’s macroglobulinaemia (WM) is a rare disease that accounts for 1%–2% of non-Hodgkin lymphomas. The reported age-adjusted incidence rate is 3.4 per million among the male population and 1.7 per million among the female population in the United States, and 7.3 and 4.2 per million, respectively, in the European standard population [1, 2]. In contrast to multiple myeloma, WM prevalence is higher among Caucasians than among African-Americans (IRR: 1.75) [3]. WM is a disease of the elderly, with the median age at the time of diagnosis being 63–75 years in different series [3–5]. Full-Text PDF Open Archive